Chinese Cancer Biologics (Global Competitors)
Geography: Asia Pacific · East Asia · China
China's biotech industry went from 'me too' (copying existing drugs) to 'first in class' (inventing new ones) in 14 years. Betta Pharma's Conmana (2011) was a domestic-market variation. BeiGene's Brukinsa (2019) went global. Now Akeso's ivonescimab — a bispecific antibody with a novel mechanism — is challenging Keytruda ($25B annual sales) in head-to-head trials.
Legend Biotech's Carvykti, a CAR-T cell therapy developed in Xi'an and commercialized globally with Johnson & Johnson, has treated over 5,000 cancer patients in 36+ countries. The $5B licensing deal between Akeso and Summit Therapeutics for ivonescimab's global rights shows Western pharma betting on Chinese drug innovation.
The structural shift: China's biotech companies are no longer licensing Western drugs for the domestic market. They're licensing Chinese drugs to Western companies for global markets. The direction of technology transfer has reversed.
Research this in Signals
Signals turns a topic into a sourced research record you can inspect and rerun. Your first scan is free, and this one starts with Chinese Cancer Biologics (Global Competitors) already loaded, so edit it or scan as is.